Non-Alcoholic Steatohepatitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market Report Overview
The Non-Alcoholic Steatohepatitis (NASH) clinical trial market research report provides an overview of the NASH clinical trials scenario. The report provides top-line data relating to the clinical trials on NASH. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
NASH Clinical Trials Market Segmentation by Regions and Countries
The key regions in the NASH clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America, among others. As of March 2023, out of all the clinical trials conducted on NASH, the majority were conducted in North America.
As of March 2023, in the country-wise analysis, the US has the highest number of NASH clinical trials and Spain has the highest average patient enrollment. The other countries included are Japan, China, the UK, Australia, France, Canada, Germany, and Belgium.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of NASH to gastrointestinal clinical trials as of March 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of NASH to gastrointestinal clinical trials as of March 2023.
NASH Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the NASH clinical trials market, download a free report sample
NASH Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the NASH clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the NASH clinical trials market.
NASH Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the NASH clinical trials market, download a free report sample
NASH Clinical Trials Market - Competitive Landscape
The leading sponsors in the NASH clinical trials market are Pfizer Inc, ICON Plc, Gilead Sciences Inc, Novartis AG, Novo Holdings AS, and Thermo Fisher Scientific Inc among others. Pfizer Inc has conducted the highest number of NASH clinical trials as of March 2023, followed by ICON Plc and Gilead Sciences Inc.
NASH Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the NASH clinical trials market, download a free report sample
NASH Clinical Trials Market Report Overview
Key Regions | Europe, North America, The Middle East & Africa, Asia-Pacific, and South & Central America |
Key Countries | The US, China, Japan, the UK, Australia, France, Canada, Germany, and Belgium |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Pfizer Inc, ICON Plc, Gilead Sciences Inc, Novartis AG, Novo Holdings AS, and Thermo Fisher Scientific Inc |
Segments Covered in the Report
NASH Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
NASH Clinical Trials Country Outlook (2023)
- The US
- China
- Japan
- The UK
- Australia
- Canada
- France
- Germany
- Belgium
NASH Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) about the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
ICON Plc
Gilead Sciences Inc
Novartis AG
Novo Holdings AS
Thermo Fisher Scientific Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Laboratory Corp of America Holdings
C. H. Boehringer Sohn AG & Co KG
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the NASH clinical trials market?
The key regions in the NASH clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America.
-
Which are the key countries in the NASH clinical trials market?
The key countries in the NASH clinical trials market are the US, China, Japan, the UK, Australia, France, Canada, Germany, and Belgium.
-
What are the key sponsor types in the NASH clinical trials market?
The key sponsor types in the NASH clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the NASH clinical trials market?
Some of the leading sponsors in the NASH clinical trials market are Pfizer Inc, ICON Plc, Gilead Sciences Inc, Novartis AG, Novo Holdings AS, and Thermo Fisher Scientific Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Non-Alcoholic Steatohepatitis (NASH) reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)